CRDL

Cardiol Therapeutics

0.9941 USD
+0.0241
2.48%
At close Apr 22, 4:00 PM EDT
1 day
2.48%
5 days
-4.41%
1 month
-11.24%
3 months
-24.69%
6 months
-46.84%
Year to date
-27.44%
1 year
-43.52%
5 years
-58.41%
10 years
-58.41%
 

About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Employees: 18

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

3,660% more call options, than puts

Call options by funds: $188K | Put options by funds: $5K

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

3% more funds holding

Funds holding: 40 [Q3] → 41 (+1) [Q4]

2.05% more ownership

Funds ownership: 7.12% [Q3] → 9.17% (+2.05%) [Q4]

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

3% less capital invested

Capital invested by funds: $9.85M [Q3] → $9.59M (-$265K) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$9
805%
upside
Avg. target
$9
805%
upside
High target
$9
805%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Vernon Bernardino
15% 1-year accuracy
11 / 71 met price target
805%upside
$9
Buy
Reiterated
16 Apr 2025

Financial journalist opinion

Based on 3 articles about CRDL published over the past 30 days

Neutral
Zacks Investment Research
9 hours ago
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
Neutral
Newsfile Corp
6 days ago
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Neutral
Newsfile Corp
3 weeks ago
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025 CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditis Cash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3 2026 Toronto, Ontario--(Newsfile Corp. - April 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today its year-end 2024 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2024. Both are available under the Company's profile on EDGAR at www.sec.gov, on SEDAR+ at sedarplus.ca and on the Company's website at cardiolrx.com.
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Positive
Proactive Investors
2 months ago
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new research published in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS) supports the potential of its cannabidiol-based drug candidate CRD-38 to treat heart failure. The study, conducted by scientists at Tecnológico de Monterrey in collaboration with researchers from the DeBakey Heart and Vascular Center in Houston, found that pharmaceutically manufactured cannabidiol, administered subcutaneously, helped preserve mitochondrial function and calcium handling in a preclinical model of heart failure.
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure
Neutral
Newsfile Corp
2 months ago
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.org/doi/abs/10.1016/j.jacbts.2024.12.009). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company's proprietary subcutaneous ("SubQ") formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction.
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Positive
Seeking Alpha
2 months ago
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts
Cardiol Therapeutics' CardiolRx™ shows promise in treating heart conditions, with ongoing clinical trials for pericarditis, myocarditis, and heart failure, and orphan drug status boosting its potential. Despite a 40% stock price decline, the market undervalues Cardiol's pipeline, with upcoming trial data and potential partnerships as catalysts for appreciation. The company is well-funded, with $15.9 million in cash reported as of 9/30/24, sufficient to meet milestones into 2026, and has a market cap of $99 million.
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts
Neutral
Newsfile Corp
2 months ago
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
Zacks Investment Research
2 months ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Neutral
GlobeNewsWire
4 months ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Charts implemented using Lightweight Charts™